# Drug regulator bars cough syrup ingredient shipments without digital clearance 2026-11-02T16:01:25+00:00 | Governance | Indian Opinion Desk Corroboration: 2 independent outlets India’s drug regulator has told manufacturers and suppliers of high-risk cough syrup ingredients that no batch can be shipped until it is registered and cleared through the government’s Digital Monitoring System (DMS). The order, issued on 27 October by Drugs Controller General Rajeev Raghuvanshi, covers propylene glycol, glycerine, maltitol and sorbitol. Makers must now upload batch quantity, lab test results and buyer details before a No Objection Certificate is generated. State drug controllers have been directed to ensure strict compliance. The move follows the deaths of at least 24 children in Madhya Pradesh and Rajasthan in 2025 after consuming cough syrups contaminated with diethylene glycol and ethylene glycol. In 2022, similar contamination in Gambia and Uzbekistan killed dozens of children. Industry bodies back the tighter traceability but warn that delays in portal clearances could temporarily disrupt raw material supplies. India’s pharmaceutical market is valued at $60 billion, and the country supplies 20% of the world’s generic medicines by volume. ## Indian Opinion Analysis Both Mint and Business Standard report the CDSCO’s digital batch clearance mandate for high-risk pharmaceutical solvents factually, with no discernible editorial slant. Mint leads with the 27 October order and the 24 child deaths linked to contaminated cough syrups in 2025, while Business Standard foregrounds the chronology of reforms after the Chhindwara deaths. Mint includes the industry’s concern about portal delays and names two executives, Business Standard adds a Delhi-based executive’s view and notes the ₹7,000-crore cough-cold market. The coverage is uniform straight reporting: both outlets quote the same DCGI letter and list the same solvents. The differences are in arrangement, not in framing. Neither outlet omits or overstates any aspect, together, they confirm the order’s scope, the compliance timeline and the industry’s dual response of backing traceability while flagging short-term supply risks. ## Coverage Coverage: 2 sources, 2 neutral - livemint.com (neutral report) Neutral-report, straight agency-style reporting - business-standard.com (neutral report) Neutral-report, straight agency-style reporting This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Tags: CDSCO, DCGI, propylene glycol, Rajeev Singh Raghuvanshi Canonical: https://indianopinion.org/drug-regulator-bars-cough-syrup-ingredient-shipments-without-digital-clearance/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/drug-regulator-bars-cough-syrup-ingredient-shipments-without-digital-clearance/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/